Related Experiment Video
Updated: Apr 16, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Cancer genomics: the challenge of drug accessibility
1Bras Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Purpose Of Review:
Although significant strides have been made in genome sequencing technology, target-drug matching remains challenging. This article highlights the difficulties associated with patients accessing targeted drugs based on genomic information, and some proposed solutions.
Recent Findings:
Although cancers are increasingly stratified according to molecular subgroups, challenges remain in improving patient outcome based on drug-target matching. Before a drug-target match is even proposed, significant expertise is required of the clinician to interpret genomic information. Once a potential match is made, barriers remain for patients to access treatment via clinical trials, as approved agents on-label or off-label, or through expanded access programs. Solutions to improve drug accessibility are actively being investigated. Several prospective trials using molecular characterization as an entry to access target-drug matching are underway. For those unable to access target-drug matching on trial, proposals for a facilitated access program and registry have been suggested.
Summary:
Although improvements have been made in the drug development and approval timelines, drug accessibility based on molecular characterization remains problematic. However, with the emergence of novel trial designs, and efforts to enhance drug access outside of clinical trial settings, opportunities for drug-target matching are improving.
Insights
Genomic sequencing advances cancer treatment, but matching patients to targeted drugs remains difficult. Improving access to these precision medicines through novel trials and programs is crucial for better patient outcomes.
Area of Science:
- Genomic medicine
- Precision oncology
- Drug discovery and development
Background:
- Cancer treatment is increasingly stratified by molecular subgroups.
- Genome sequencing technology has advanced significantly.
- Target-drug matching for cancer patients presents ongoing challenges.
Purpose of the Study:
- To highlight the difficulties patients face in accessing targeted drugs based on genomic information.
- To discuss proposed solutions for improving drug accessibility.
- To review the current landscape of drug-target matching in oncology.
Main Methods:
- Review of current literature on genomic sequencing and targeted therapies.
- Analysis of barriers to accessing targeted cancer drugs.
- Discussion of emerging solutions and clinical trial designs.
Main Results:
- Interpreting genomic data requires significant clinical expertise.
- Patients face substantial barriers accessing targeted treatments via clinical trials, on-label/off-label approvals, or expanded access.
- Prospective trials utilizing molecular characterization for drug matching are in progress.
- Facilitated access programs and registries are proposed to address access gaps.
Conclusions:
- Despite advances in drug development, molecularly-guided drug accessibility remains a significant issue.
- Novel clinical trial designs and enhanced access strategies outside of traditional trials are improving opportunities for drug-target matching.
- Continued efforts are needed to bridge the gap between genomic insights and patient access to targeted therapies.
Related Concept Videos
02:18Cancer
02:56Treatment Resistant Cancers
01:29Pharmacogenomics: Identification of New Drug Targets
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
02:57Targeted Cancer Therapies